Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06543914 · ClinicalTrials.gov registry record
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
A clinical trial of Migraine, sponsored by AbbVie.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 20
- Study locations
NCT06543914: Recruiting study of Migraine, sponsored by AbbVie.
NCT06543914 is a study of Migraine that is actively recruiting participants, run by AbbVie. The registered enrollment target is 1,000 participants, above the 348-participant average among 102 other Migraine trials with a reported enrollment target (187% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06543914, a study of Migraine, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 1000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study across the world. Participants will receive atogepant oral tablets as prescribed per standard clinical practice and will be followed for 2 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Primary Outcome
PGI-C is a single item used to measure the patient's impression of overall change in migraine since the first dose of atogepant. The measure uses a 7-point rating scale with responses ranging from "very much better" to "very much worse".
Conditions Studied
Study Locations (20)
New York
- Dent Neurologic Institute - Amherst /ID# 267606 - Amherst
- Northwell Health - Great Neck /ID# 280705 - Great Neck
- Northwell Health /ID# 267596 - New York
Alabama
- Neurology and Neurodiagnostics of Alabama /ID# 267614 - Hoover
- Rehabilitation & Neurological Services /ID# 267612 - Huntsville
California
- Kenneth Martinez MD, A Medical Corp /ID# 267834 - Aliso Viejo
- Los Angeles Headache Center /ID# 267570 - Los Angeles
Brussels Capital
- Cliniques Universitaires UCL Saint-Luc /ID# 270545 - Brussels
- Universitair Ziekenhuis Brussel /ID# 269799 - Jette
Liege
- Centre Hospitalier Régional de la Citadelle /ID# 270539 - Liège
- Groupe Sante CHC - Clinique du MontLegia /ID# 270218 - Liège
Arizona
- Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 267610 - Phoenix
Florida
- Alcanza Clinical Research, LLC /ID# 267838 - Lake Mary
Kentucky
- Norton Cancer Institute - St. Matthews /ID# 267605 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2029-02 |
What NCT06543914 shows while recruiting
NCT06543914 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 348-participant average among 102 other Migraine trials with a reported enrollment target (187% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 0 interventions.
NCT06543914 names 20 study sites across 14 states, led by New York, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT06543914 about?
NCT06543914 is a clinical study titled "Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine". Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an app...
What is the current status of trial NCT06543914?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-11-26. Estimated completion is 2029-02.
What conditions does trial NCT06543914 study?
This clinical trial studies the following conditions: Migraine.
Who is sponsoring clinical trial NCT06543914?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06543914 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06543914's enrollment target sits among peer trials
1,000 11th of 102 higher than 92 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI